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Abstract
Background: Sertraline is primarily used to treat major depression in adult outpatients as well as obsessive-
compulsive, panic and social anxiety disorders in both adults and children. A survey of the literature reveals that
most of the reported methods are either insufficiently sensitive or tedious and require highly sophisticated and
dedicated instrumentation. The proposed method is considered to be specific for determination of SER in presence
of its metabolite (deaminated form).
Results: A sensitive, simple and specific spectrofluorimetric method was developed for the determination of
sertraline (SER) in pharmaceutical formulations and biological fluids. The method is based on its reaction with 9-
fluorenylmethyl chloroformate (FMOC-Cl) in borate buffer of pH 8.0 to yield a highly fluorescent derivative peaking
at 315 nm after excitation at 265 nm. The different experimental parameters affecting the development and
stability of the reaction product were carefully studied and optimized. The fluorescence concentration plot was
rectilinear over the range of 0.05-1.0 μgm L
-1 with a lower detection limit of 5.34 × 10
-3 μgm L
-1 and limit of
quantitation of 0.016 μgm L
-1.
Conclusions: The proposed method was successfully applied to the analysis of commercial tablets and the results
obtained were in good agreement with those obtained using the reference method. Furthermore, the method was
applied for the determination of SER in spiked and real human plasma. The mean % recovery (n = 3) was 94.33 ±
1.53 and 92.00 ± 2.65, respectively. A proposal of the reaction pathway was postulated.
Background
Sertraline (SER); (1S)-cis-4-(3,4-dichlorophenyl)-1,2,3,4-
tetrahydro-N-methyl-1-naphthalenamine (Figure 1) is
primarily used to treat major depression in adult outpa-
tients as well as obsessive-compulsive, panic and social
anxiety disorders in both adults and children. The effi-
cacy of sertraline for depression is similar to that of
older tricyclic antidepressants, but its side effects are
much less pronounced [1].
Several methods have been reported for the determi-
nation of SER either per se or in pharmaceutical pre-
parations and biological fluids. These methods include:
spectrophotometry [2-4], voltammetry [5], HPLC [6-11]
gas chromatography [12,13]. A literature review up to
2008 has been described by Espinosa et al [14]. The
review described the different analytical methodologies
for the determination of SER chromatography [14]and
liquid mass spectrometry [15,16].
Most of these methods are either insufficiently sensi-
tive [2-4] or tedious and require highly sophisticated
and dedicated instrumentation [6-16]. This led us to
study the reaction of sertraline with 9-fluorenylmethyl
chloroformate (FMOC-Cl) in an attempt to develop a
simple and sensitive spectrofluorimetric method for its
determination in pharmaceutical preparations and biolo-
gical fluids.
9-Fluorenylmethyl chloroformate is a useful derivatiz-
ing agent used for the determination of amino acids,
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ceutical compounds have been determined through this
approach [16-21].
To the best of our knowledge, up till now nothing has
been reported concerning the spectrofluorimetric deter-
mination of sertraline. This encouraged us to develop a
simple and sensitive method for its determination in
tablets and human plasma. The results obtained were
promising.
Experimental
Instrumentation
The fluorescence spectra and measurements were
recorded using a Perkin-Elmer UK model LS 45 lumi-
nescence spectrometer, equipped with a 150 Watt
Xenon arc lamp, grating excitation and emission
monochromators for all measurements and a Perkin-
Elmer recorder. Slit widths for both monochromators
were set at 10 nm. A 1 cm quartz cell was used. Deri-
vative spectra were evaluated using Fluorescence Data
Manager (FLDM) software. Sofware used is FL WIN-
LAB, Version 4.00.02, copyright 2001, Perkin Elmer,
Inc., UK.
Reagents and materials
All reagents and solvents used were of Analytical
Reagent grade.
(a) Setraline pure sample was kindly provided by Pfi-
zer (Sandwich, UK).
(b) Tablets containing sertraline HCl equivalent to 50
mg of sertraline base each (Lustral
® tablets), batch #
7201 were obtained from commercial sources in the
local market.
(c) 9-fluorenylmethyl chloroformate (FMOC-Cl), was
purchased from Sigma (St. Louis USA). A stock solution
containing 20 mg % of FMOC-Cl was freshly prepared
in acetonitril and was further diluted with the same sol-
vent to obtain 0.01 mg % solution.
(d) Borate buffer 0.2 M solutions of pH 8.0. and pH
12.
(e) Acetonitrile, acetone and diethylether (Merck,
Darmstadt, Germany).
(f) Human plasma samples were kindly provided by
Mansoura University Hospital, Mansoura, Egypt and
was kept frozen at -2°C until assay after gentle thawing.
Standard Solutions
A stock solution was prepared by dissolving 20.0 mg of
SER in 100 mL of acetonitrile in a volumetric flask. This
solution was further diluted with the same solvent as
appropriate. The standard solutions were stable for
seven days when kept in the refrigerator.
General recommended procedures
Procedure for calibration graph
Aliquots of SER standard solutions were transferred into
as e r i e so f1 0m Lv o l u m e t r i cf l a s k s .B o r a t eb u f f e r ,p H
8.0 (2.5 mL) was added, followed by FMOC-Cl (0.01 mg
%) (2 mL) and mixed well. Acetonitril (3 mL) were
added. The reaction mixture was left at room tempera-
ture for 15 min., and then completed to the mark with
distilled water. The fluorescence intensity of the reaction
product was measured at 315 nm after excitation at 265
nm. A blank experiment was carried out simultaneously.
The corrected fluorescence intensity was plotted vs the
final drug concentration (μgm L
-1) to get the calibration
graph. Alternatively, the corresponding regression equa-
tion was derived.
Assay procedure for Tablets
Twenty tablets were weighed and pulverized well. A
weighed quantity of the “powder, equivalent” to 20.0 mg
of SER was transferred into a small conical flask, and
extracted with 3 × 30 mL of actonitril. The extract was
filtered into 100 mL volumetric flask. The conical flask
was washed with few milliliters of acetonitril. The wash-
ings were passed into the same volumetric flask and
made up the mark with the same solvent. Aliquots cov-
ering the working concentration range was transferred
into 10 mL volumetric flasks. The procedure described
under “ General recommended procedures”“ was then
applied. The nominal content of the tablets was deter-
mined either from the calibration curve or by using the
corresponding regression equation.
Assay procedure for spiked human plasma
A stock solution containing 20.0 μgm L
-1 of SER was
prepared in acetonitrile. Control samples of plasma were
spiked with different quantities of SER. Acetone (2 mL)
was added, then the mixture was vortexed and centri-
fuged at 3500 xg for 10 min. 3 mL of the clear superna-
tant was separated, and borate buffer, pH 12 (1 mL)was
NH
Cl
Cl
Figure 1 Structural formula of Sertraline.
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diethylether for 2 min, then centrifuged at 3500 xg for 5
min. The resulting supernatant was evaporated to dry-
ness under nitrogen at ambient temperature. The resi-
due was dissolved in 2 mL of acetonitrile. The general
recommended procedures applied for pure sample were
then performed. The nominal content of the drug was
determined using the corresponding regression equation.
Assay procedure for real human plasma samples
As for the real human plasma, SER (50 mg/tablet) was
orally administered to a fasting healthy volunteer (male,
40 years old). 5 mL of blood sample was withdrawn
after four hours. Then, 4 mL of citrate solution was
added, and centrifuged at 3500 rpm for 15 min. to
obtain ca 3 mL of plasma. The methodology described
under the “procedure for spiked human plasma” was
then carried out. The nominal content of SER in plasma
was determined according to previous report [22] using
the following equation:
Recovery invivo = Deliveryinvivo × Recoveryinvitro/Deliveryinvitro
This means that % recovery for SER in real human plasma =
Concentration of the drug in real plasma X % recovery in spiked plasma
Concentration of the drug in spiked plasma
Results and Discussion
FMOC-Cl was chosen as a fluoregnic derivatizing agent
for SER because of its superior properties, as compared
to other reagents. It reacts under mild conditions with
primary and secondary amines in alkaline medium and
the resulting derivatives are stable.
It has been utilized for the determination of amino
acids and primary amines [16]. Recently FMOC-Cl was
further used for the analysis of some pharmaceutical
compounds containing primary or secondary amino
groups viz; trimetazine [17] roxithromycin [18] clari-
thromycin [19] alendronate [20] and topiramate [21].
In the present study, SER was found to react with
FMOC-Cl at pH 8.0 forming a highly fluorescent deriva-
tive with l maximum of 315 nm after excitation at 265
nm (Figure 2).
Study of Experimental Parameters
The spectrofluorimetric properties of the reaction product
as well as the different experimental parameters affecting
its development and its stability were carefully studied and
optimized. Such factors were changed individually while
the others were kept constant. The factors included pH,
type of buffer, volume of buffer, concentration of the
reagent, reaction time and volume of acetonitrile.
i. Effect of pH
The influence of pH on the fluorescence intensity of the
reaction product was evaluated. Maximum fluorescence
intensity was obtained at pH 7.8 and remained constant
up to 8.2 after which the fluorescence intensity of the
reaction product began to decrease gradually until pH
13. Therefore, pH of 8.0 was chosen as the optimum pH
(Figure 3). Other buffers having the same pH value such
as phosphate and hexamine were tried and compared
with 0.2 M borate buffer. Borate buffer was found to be
superior to phosphate and hexamine buffers having the
same pH value since the net fluorescence intensity was
highest in the case of borate buffer.
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Figure 2 Fluorescence spectra of excitation and emission.( A )
Excitation spectra of blank (B) Emission spectra of blank (A’)
Excitation spectra of SER (1 μgm L
-1) with FMOC-Cl at pH 8.0 (B’)
Emission spectra of SER (1 μgm L
-1) with FMOC-Cl at pH 8.0.
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Figure 3 Effect of pH on the fluorescence intensity of SER (1
μgm L
-1) with FMOC-Cl.
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It was found that increasing the volume of 0.2 M borate
buffer of pH 8.0 up to 2 mL resulted in a gradual
increase in the fluorescence intensity of the reaction
product and after which it remained constant till 3 mL,
therefore 2.5 mL of the buffer was chosen as the opti-
mal volume throughout the study.
iii. Effect of concentration of FMOC-Cl
The influence of the concentration of FMOC-Cl was
studied using different volumes of 0. 01 mg % of the
reagent solution. It was found that the reaction of
FMOC-Cl with SER started upon using 0.25 mL of the
reagent in the presence of borate buffer (pH 8.0).
Increasing the volume of the reagent produces a propor-
tional increase in the fluorescence intensity of the reac-
tion product up to 1.8 mL and remains constant up to
2.2 mL. Therefore, 2 mL of 0.01 mg % of FMOC-Cl
solution was chosen as the optimal volume of the
reagent.
iv. Effect of temperature
Increasing the reaction temperature higher than the
room temperature up to boiling for 20 minutes. resulted
in a subsequent decrease in the fluorescence intensity of
the reaction product.
v. Effect of reaction time
Different time intervals were tested to ascertain the time
after which the solution attained its highest fluorescence
intensity. It was found that after 10 minutes the reaction
product reached the highest fluorescence intensity and
remained stable up to 20 min, after which very slight
decrease in the fluorescence intensity of the reaction
product was observed (Figure 4). Therefore, the reaction
product was measured after 15 min at room tempera-
ture (25°C).
vi. Effect of volume of acetonitril
It was found that, 3 mL of acetonitril was sufficient to
produce maximum and constant fluorescence intensity
of the reaction product. The reaction between FMOC-
Cl and SER takes place in an aqueous -organic phase
system due to insolubility of FMOC-Cl and reaction
product in water. It was necessary to perform the reac-
tion with high content of acetonitril (final concentration,
60%)
Validation of the proposed method
The validity of the method was tested regarding; linear-
ity, specificity, accuracy, repeatability and precision
according to ICH Q2B recommendations [23].
Linearity
By using the above procedure, linear regression equation
was obtained. The regression plots showed that there
was a linear dependence of the fluorescence intensity on
the concentration of the drug over the ranges shown in
Table 1linear to coefficient is superfluous as data is
already in the table. A linear regression analysis of the
data gave the following equation:
F= − 0.66 + 346C (r = 0.9999)
where F is the fluorescence intensity, C is the concen-
tration of the drug in μg/ml and r is the correlation
coefficient.
The limit of quantification (LOQ) was determined by
establishing the lowest concentration that can be mea-
sured according to ICH Q2B [23]. The results are
shown in Table 1. The limit of detection (LOD) was
determined by establishing the minimum level at which
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Figure 4 Effect of reaction time of on the fluorescence intensity of the reaction product of SER (1 μgm L
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also abridged in Table 1.
LOQ and LOD were calculated according to the fol-
lowing equation: [23]
LOQ = 10σ/S
LOD = 3.3σ/S
Where s: is the standard deviation of the intercept of
regression line.
S: is the slope of the calibration curve.
The proposed methods were evaluated for the accu-
racy as percent relative error (% Error) and the precision
as percent relative standard deviation (% RSD) (Tables 1
and 2).
Accuracy
To test the validity of the proposed method, it was
applied to the determination of an authentic sample of
SER over the working concentration range. The results
obtained were in good agreement with those obtained
using a reference method.
11).U s i n gS t u d e n t ’st - t e s ta n d
variance ratio F-test [24] revealed no significant
difference between the performance of the two methods
regarding the accuracy and precision, respectively (Table
2).
The validity of the methods was proved by statistical
evaluation of the regression lines, using the standard
deviation of the residuals (Sy/x), the standard deviation
of the intercept (Sa) and standard deviation of the slope
(Sb). The results are abridged in Table 1. The small
values of the figures point out to the low scattering of
the points around the calibration line and high
precision.
Precision
i. Repeatability
The repeatability was performed by applying the pro-
posed methods for the determination of three concen-
trations of SER either in pure form or in tablets on
three successive times, and the results are listed in
Table 3.
ii. Intermediate precision
It was performed through repeated analysis of SER
either in pure form or in tablets, using the concentra-
tions showed in Table 3 for a period of 3 successive
days. The results are summarized in Table 3.
Pharmaceutical Applications
The proposed methods were then applied to the deter-
mination of SER in its tablets. The methods were tested
Table 1 Performance data of the proposed method
Parameter Value
-concentration range (μgm L
-1). 0.05-1.0
-Minimum detection limit, LOD (μgm L
-1 ). 5.34 × 10
-3
-Limit of Quantification, LOQ(μgm L
-1). 0.016
-Correlation coefficient (r). 0.9999
-Slope 345.9
-Intercept -0.66
-Sy/x 0.89
-Sa 0.56
-Sb 0.99
-% Error 0.34
-Sy/x = standard deviation of the residuals.
-Sa = standard deviation of the intercept of regression line.
-Sb = standard deviation of the slope of regression line
-% Error = RSD%/√ n.
Table 2 Application of the proposed and reference
methods to the determination of sertraline in pure form
Parameters Spectrofluorimetric Method Reference
Method (11)
1-No.of Experiments. 7 3
2-Mean found (%) 100.31 99.92
± SD. 0.90 1.58
% R.SD. 0.90 1.58
3-Variance. 0.81 2.496
4-Student’s t-value. 0.51 (2.31)
5-Variance ratio F-test. 3.08 (5.14)
Figures between parentheses are the tabulated t and F values respectively, at
p = 0.05 [24].
Table 3 Validation of the proposed method for the
determination of sertraline in pure form and tablets
Concentration added
(μgm L
-1)
% Recovery % RSD % Error
SER
Intra-day
0.2 98.75 ± 0.65 0.65 0.33
0.4 100.41 ± 1.07 1.07 0.54
0.6 98.66 ± 0.5 0.5 0.25
Inter-day
0.2 99.98 ± 0.82 0.82 0.41
0.4 100.63 ± 0.85 0.85 0.43
0.6 100.74 ± 1.17 1.17 0.59
Lustral Tablets
(50 mg SER/tablet)
Intra-day
0.2 98.00 ± 1.29 1.29 0.65
0.4 100.41 ± 0.92 0.92 0.46
0.6 100.47 ± 1.35 1.35 0.68
Inter-day
0.20 100.19 ± 1.07 1.07 0.54
0.40 99.67 ± 1.56 1.56 0.78
0.60 100.80 ± 0.80 0.80 0.40
Each result is the average of four separate determinations.
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sion according to ICH Q2B recommendations.
Selectivity
The selectivity of the method was investigated by obser-
ving any interference encountered from the common
tablet excepients, such as talc, lactose, starch, avisil,
gelatine, and magnesium stearate. These excepients did
not interfere with the proposed method
Accuracy
The results of the proposed methods were statistically
compared with those obtained using the reference
method [11]. Statistical analysis [24] of the results, using
Student’s t-test and variance ratio F-test revealed no sig-
nificant difference between the performance of the pro-
posed and reference methods regarding the accuracy
and precision, respectively (Table 4).
The reference is based on an HPLC determination of
sertraline HCl either inpure form or in its tablets using
a mobile phase consists of methanol: phosphate buffer
(20: 80 v/v) of pH 4.5 with UV detection at 270 nm.
Analysis of biological fluid
This investigation conforms to the Egyptian Community
guidelines for the use of human in experiments. The
human Ethics Committee of Faculty of Pharmacy, Man-
soura University, approved the study.
The high sensitivity of the proposed method allowed
the determination of SER in spiked and real human
plasma. Following oral administration of a single 50 mg
sertraline dose after an over night fast, the mean plasma
level of 0.05-0.2 μg/mL was achieved after 6.9 hour (25).
This values lie within the working concentration range.
Sertraline is extensively metabolized via N-desmethyla-
tion, oxidative deamination and subsequent reduction,
hydroxylation and glucuronide conjugation. About 40-
45% of an administered dose is excreted in urine as
unchanged drug [25].
The results are shown in Table 5.
The extraction procedure described by Kim et al [26]
was adopted here. The results are satisfactorily accurate
and precise.
Precision
The within-day precision was evaluated through repli-
cate analysis of blank human plasma samples spiked
with different concentrations of the drug. The percen-
tage recoveries based on the average of three separate
determinations were 94.40 ± 1.14, thus indicating the
high precision of the method (Table 5).
The inter-day precision was also evaluated through
replicate analysis of plasma samples spiked with 0.1 μg
mL
-1 of drug on four successive days. The percentage
recoveries based on the average of four separate
Table 4 Application of the proposed methods to the
determination of sertraline in tablets
% Recovery
Preparations Proposed method Reference method (11)
Lustral tablets 98.25 100.23
(50 mg sertraline /tablet) 101.00 98.51
99.38 100.43
99.80
99.30
-Mean found (%) ± SD. 99.69 ± 1.05 99.72 ± 1.06
t - value
F- value
The tabulated values of t and F are (2.45) and (6.94) respectively, at p = 0.05
(24).
Table 5 Application of the proposed methods to the
determination of sertraline in spiked and real human
plasma samples
Sample Amount
added
(μgm L
-1)
Amount
found
(μgm L
-1)
%
Recovery
1 -a-Plasma 0.05 0.048 96.0
(intra-day precision) 0.10 0.0939 93.90
0.20 0.1884 94.20
Mean 94.40
± SD 1.14
% RSD 1.14
% Error 0.66
1-b-Plasma 0.10 0.0930 93.00
(inter-day precision) 0.10 0.0957 95.70
0.10 0.0923 92.30
0.10 0.0902 90.20
Mean 92.80
± SD 2.27
% RSD 2.27
% Error 0.57
2- Real Human
plasma
0.10 0.0955 95.5
0.10 0.0912 91.20
0.10 0.090 90.00
Mean 92.23
± SD 2.89
% RSD 2.89
% Error Mean 1.67
Each result is the average of three separate determinations.
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in Table 5. On the other hand, for real human plasma,
the percentage recoveries based on the average of three
separate determinations were 92.23 ± 2.89.
Molar ratio and mechanism of the reaction
The stoichiometry of the reaction was studied adopting
the limiting logarithmic method [27]. The fluorescence
intensity of the reaction product was alternatively mea-
sured in the presence of excess of either FMOC-Cl or
SER A plot of log fluorescence versus log [FMOC-Cl]
and log [SER] gave two straight lines, the values of the
slopes are 0.707 and 0.985 respectively(Figure 5). Hence,
it is concluded that, the molar reactivity of the reaction
is 0.985/0.707, i.e. the reaction proceeds in the ratio of
1: 1. Based on the observed molar reactivity of the reac-
tion, and depending on the presence of secondary
amino group and by analogy to similar reports (18, 20)
dealing with the reaction of FMOC-Cl with compounds
containing secondary amino group, the reaction pathway
proposed in scheme 1 is presented.
Conclusion
The proposed method has the advantage of being sim-
ple, sensitive and suitable for routine analysis in quality
control laboratories. Also, iti ss u i t a b l ef o rt h ed e t e r m i -
nation of sertraline in human plasma with minimum
detection limit lower than the reported value. In addi-
tion, it could be applied to the determination of sertra-
line in its pharmaceutical preparation. The proposed
method is considered to be specific for determination of
SER in presence of its metabolite (deaminated form)
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